Ibogaine therapy carries potential risks that can be severe. Reported adverse effects include cardiac arrhythmia, seizures, respiratory depression, confusion, and impaired coordination. The concern is not theoretical: changes in heart rhythm can become life-threatening.
A responsible screening process includes a detailed medical history, current medications, blood work, liver function testing, and cardiac evaluation such as an ECG. Heart conditions, electrolyte problems, and certain drug interactions can make ibogaine hydrochloride especially dangerous.
Medical supervision must mean more than a person nearby. Clinical settings considering ibogaine need a medical doctor or other qualified healthcare personnel, emergency equipment, continuous observation, and the ability to respond to complications. Patient safety depends on that capacity.
Vital signs such as heart rate, blood pressure, and oxygenation require careful monitoring. Accounts of medically supervised ibogaine therapy commonly describe at least 24 to 72 hours of observation and follow-up care after administration.
For a broader explanation of risks and access, this guide to ibogaine rehabilitation settings outlines why clinic claims should be examined closely. Responsible use cannot be assumed from marketing language.
People with a substance use disorder deserve treatment options that account for their unique needs. Medication-assisted treatment, counseling, peer support, harm reduction, and established detox services are available pathways that do not depend on an unapproved high-risk drug.